MIR4493: A Potential Drug Target and Biomarker (G100616319)
MIR4493: A Potential Drug Target and Biomarker
MIR4493, also known as interleukin-4 receptor 7 (IL-4R7), is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and obesity. Its unique structure and subcellular localization have made it an attractive target for drug development due to its robust effects on cellular processes, including inflammation, cell survival, and metabolism.
MIR4493 is a key regulator of the interleukin-4 (IL-4) signaling pathway, which plays a crucial role in the regulation of immune and inflammatory responses. IL-4R7 is a type of IL-4 receptor that has been shown to promote the development and maintenance of regulatory T cells, a type of immune cell that help to maintain immune tolerance and prevent autoimmune diseases.
MIR4493 has been shown to promote the expression of IL-4R7 in various cell types, including natural killer cells, T cells, and cancer cells. Its localization to the nuclear envelope has also been reported, which suggests a potential role in regulating gene expression and cellular processes within the cell membrane.
In cancer, MIR4493 has been shown to promote the growth and survival of various types of cancer cells, including breast, ovarian, and colorectal cancer. Its effects on cancer cell proliferation have also been linked to the regulation of the PI3K/Akt signaling pathway, which is known to play a role in the regulation of cell survival and angiogenesis.
In autoimmune disorders, MIR4493 has been shown to contribute to the development of various autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Its effects on immune cell function and the regulation of inflammatory responses have been linked to the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12.
In obesity, MIR4493 has been shown to be involved in the regulation of energy metabolism and the production of pro-inflammatory cytokines, such as IL-6 and IL-8. Its effects on cellular processes, including the production of mitochondrial DNA, have also been linked to the regulation of energy metabolism and the development of obesity.
Due to its effects on cellular processes and its unique localization to the nuclear envelope, MIR4493 has potential as a drug target for various diseases. The development of MIR4493 inhibitors has been shown to be effective in various cellular and animal models of cancer, autoimmune disorders, and obesity.
In addition to its potential as a drug target, MIR4493 has also been identified as a potential biomarker for various diseases. Its effects on cellular processes and its localization to the nuclear envelope have been linked to the regulation of gene expression and cellular processes, which can be used as potential biomarkers for diseases.
The identification of MIR4493 as a potential drug target and biomarker has implications for the development of new treatments for various diseases. Further research is needed to fully understand the effects of MIR4493 on cellular processes and its potential as a drug target and biomarker.
Overall, MIR4493 is a non-coding RNA molecule that has shown potential as a drug target and biomarker for various diseases. Further research is needed to fully understand its effects on cellular processes and its potential as a new treatment option for a variety of diseases.
Protein Name: MicroRNA 4493
The "MIR4493 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4493 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4496 | MIR4497 | MIR4498 | MIR4499 | MIR449A | MIR449B | MIR449C | MIR4500 | MIR4500HG | MIR4501 | MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2 | MIR4509-3 | MIR450A1 | MIR450A2 | MIR450B | MIR4510 | MIR4511 | MIR4512 | MIR4513 | MIR4514 | MIR4516 | MIR4519 | MIR451A | MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677
